CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 19 enrolled
Drug / intervention
Corticotropin 80Unit/Ml Repository Injectiondrug
Likely dose
Corticotropin 80Unit/Ml Repository Injectionfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03287635
NCT03287635Phase 4Completed
CompareCT.gov

Study Title: A Phase 4 Study to Assess the Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease

Toyos Clinic·interventional·Posted Sep 19, 2017·Updated Jan 28, 2021

In Brief

A Phase 4 clinical trial evaluating Corticotropin 80Unit/Ml Repository Injection for Dry Eye Disease. Completed, enrolled 19 participants across 1 site.

Detailed Summary

Study Title: A Phase 4 Study to Assess the Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects with Dry Eye Disease

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Disease
CountriesUnited States
CollaboratorsMallinckrodt

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedSep 19, 2017
Enrollment StartJul 1, 2018
Primary CompletionFeb 1, 2020
Study CompletionMar 4, 2020
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 8.8 years ago

Interventions

Corticotropin 80Unit/Ml Repository Injectiondrug

H.P. Acthar Gel (repository corticotropin injection) is an adrenocorticotropic hormone (ACTH) analogue used for: Treatment during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus.